Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Invitae Corp (NVTA)

Invitae Corp (NVTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,207
  • Shares Outstanding, K 267,010
  • Annual Sales, $ 516,300 K
  • Annual Income, $ -3,106 M
  • EBIT $ 836 M
  • EBITDA $ 3,305 M
  • 60-Month Beta 1.59
  • Price/Sales 0.05
  • Price/Cash Flow 0.00
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.11
  • Most Recent Earnings $-0.10 on 11/08/23
  • Next Earnings Date 02/27/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.29
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.34
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +14.71%

Most Recent Stories

More News
Is Invitae Stock a Buy Now?

Invitae shares have lost more than 80% over the past year and a half.

NVTA : 0.0195 (+2.63%)
5 Cathie Wood Stocks Analysts Expect to Rally

These 5 stocks from the maverick investor's flagship ARKK fund have gained a vote of confidence from analysts, with Wall Street predicting significant upside potential from current levels.

NVDA : 134.70 (+3.08%)
TSLA : 421.06 (-3.46%)
U : 22.51 (+1.12%)
NVTA : 0.0195 (+2.63%)
ACHR : 9.49 (+12.71%)
EXAS : 59.40 (+5.86%)
TTD : 125.01 (-0.97%)
SQ : 89.65 (+2.29%)
DKNG : 40.35 (+2.41%)
Better Growth Stock: CRISPR Therapeutics vs. Invitae

One of these stocks may be riskier than the other...

AAPL : 254.49 (+1.88%)
AMZN : 224.92 (+0.73%)
VRTX : 397.27 (+0.16%)
CRSP : 40.72 (+0.83%)
NVTA : 0.0195 (+2.63%)
1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

NVDA : 134.70 (+3.08%)
TSLA : 421.06 (-3.46%)
U : 22.51 (+1.12%)
NVTA : 0.0195 (+2.63%)
ARKK : 59.40 (+2.11%)
$NASX : 19,572.60 (+1.03%)
RXRX : 6.03 (-0.99%)
Invitae (NVTA) Q3 2023 Earnings Call Transcript

NVTA earnings call for the period ending September 30, 2023.

NVTA : 0.0195 (+2.63%)
Invitae: Q3 Earnings Snapshot

Invitae: Q3 Earnings Snapshot

NVTA : 0.0195 (+2.63%)
3 Things About Invitae Every Smart Investor Knows

The last two years have been tumultuous, and there are no calm waters in sight.

NVTA : 0.0195 (+2.63%)
Is Invitae Stock a Buy Now?

Invitae shares have dropped more than 60% this year.

NVTA : 0.0195 (+2.63%)
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D.,...

NVTA : 0.0195 (+2.63%)
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced results of its collaborative study on universal hereditary cancer...

NVTA : 0.0195 (+2.63%)

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 0.0195
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.0247
Fibonacci 61.8% 0.0210
Fibonacci 50% 0.0199
Last Price 0.0195
Fibonacci 38.2% 0.0187
52-Week Low 0.0150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar